/
Nephrology
Kidney Disease
162
Pipeline Programs↗
276
Active Trials↗
128
Companies Involved↗
Kidney Disease is a highly competitive landscape with 162 programs across 128 companies. The most active players are GSK, Bristol-Myers Squibb, Shaanxi Micot Pharmaceutical Technology Co., Ltd.. 27 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical87
Phase 124
Phase 224
Phase 327
Approved
No programs
Analysis
Modality Breakdown
91%
Small molecule
137 of 150 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 150 classified programs, each share of the total. Modality classified for 98% of 162 pipeline programs.
Analysis
Trial Status
1,018
clinical trials
Completed534 · 52%
Recruiting138 · 14%
Unknown status84 · 8%
Terminated82 · 8%
Not yet recruiting77 · 8%
Active, not recruiting54 · 5%
Other49 · 5%
Clinical Trials
Trial Activity
1018 trials
Physical Exercise in Hemodialysis Patients in End Stage Kidney Disease
Recruiting·—·Preclinical·NCT07820514·312 enrolled
Page 1 of 68
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)